Dept of Medicine, Faculty of Medicine and Health Sciences, University of Auckland, Auckland, NZ.
Dept of Medicine, Faculty of Medicine and Health Sciences, University of Auckland, Auckland, NZ.
Heart Lung Circ. 2022 Jun;31(6):779-786. doi: 10.1016/j.hlc.2022.01.015. Epub 2022 Mar 10.
Diagnosis and prognostication in acute coronary syndromes (ACS) is achieved using a combination of clinical factors and biomarkers, notably cardiac troponin and B type natriuretic peptide and its N terminal fragment NT-proBNP. However, there are numerous biomarkers that have been shown to be associated with ACS, with variable incremental utility. This brief review focusses on some promising emerging biomarkers in ACS, discussed according to pathophysiologic mechanism, as well as diagnostic and prognostic utility.
急性冠状动脉综合征 (ACS) 的诊断和预后是通过临床因素和生物标志物的组合来实现的，特别是肌钙蛋白和 B 型利钠肽及其 N 末端片段 NT-proBNP。然而，有许多生物标志物已被证明与 ACS 相关，其增量效用各不相同。本简要综述根据病理生理机制以及诊断和预后效用，讨论了 ACS 中一些有前途的新兴生物标志物。
